Swift CC, Eklund MJ, Kraveka JM, Alazraki AL. Updates in diagnosis, management, and treatment of neuroblastoma. Radiographics. 2018;38:566–80. https://doi.org/10.1148/rg.2018170132.

Article  PubMed  Google Scholar 

Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17:369–86. https://doi.org/10.1080/14737140.2017.1285230.

Article  CAS  PubMed  Google Scholar 

Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625–34. https://doi.org/10.1200/jco.2009.27.0421.

Article  PubMed  PubMed Central  Google Scholar 

Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24:65–86. https://doi.org/10.1016/j.hoc.2009.11.011.

Article  PubMed  Google Scholar 

DuBois SG, Macy ME, Henderson TO. High-risk and relapsed neuroblastoma: toward more cures and better outcomes. Am Soc Clin Oncol Educ Book. 2022;42:1–13. https://doi.org/10.1200/EDBK_349783.

Article  PubMed  Google Scholar 

Ladenstein R, Potschger U, Valteau-Couanet D, Luksch R, Castel V, Ash S, et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers (Basel). 2020;12(2):309. https://doi.org/10.3390/cancers12020309.

Article  CAS  PubMed  Google Scholar 

Bellini A, Pötschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, et al. Frequency and prognostic impact of alk amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). J Clin Oncol. 2021;39:3377–90. https://doi.org/10.1200/jco.21.00086.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hogarty MD, Brodeur GM. Chapter 457. Neuroblastoma. In: Rudolph CD, Rudolph AM, Lister GE, First LR, Gershon AA, editors. Rudolph’s Pediatrics. 22nd ed. New York: The McGraw-Hill Companies; 2011.

Google Scholar 

Smith V, Foster J. High-risk neuroblastoma treatment review. Children (Basel). 2018;5(9):114. https://doi.org/10.3390/children5090114.

Article  PubMed  Google Scholar 

Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol. 2009;27:1007–13. https://doi.org/10.1200/JCO.2007.13.8925.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant. 2008;41:159–65. https://doi.org/10.1038/sj.bmt.1705929.

Article  CAS  PubMed  Google Scholar 

Stram DO, Matthay KK, O’Leary M, Reynolds CP, Haase GM, Atkinson JB, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children’s Cancer Group studies. J Clin Oncol. 1996;14:2417–26. https://doi.org/10.1200/JCO.1996.14.9.2417.

Article  CAS  PubMed  Google Scholar 

Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341:1165–73. https://doi.org/10.1056/NEJM199910143411601.

Article  CAS  PubMed  Google Scholar 

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34. https://doi.org/10.1056/NEJMoa0911123.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ladenstein R, Potschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1617–29. https://doi.org/10.1016/S1470-2045(18)30578-3.

Article  CAS  PubMed  Google Scholar 

Ladenstein R, Potschger U, Pearson ADJ, Brock P, Luksch R, Castel V, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18:500–14. https://doi.org/10.1016/S1470-2045(17)30070-0.

Article  CAS  PubMed  Google Scholar 

Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322:746–55. https://doi.org/10.1001/jama.2019.11642.

Article  PubMed  PubMed Central  Google Scholar 

Yalcin B, Kremer LC, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev. 2015;2015: CD006301. https://doi.org/10.1002/14651858.CD006301.pub4.

Article  PubMed  PubMed Central  Google Scholar 

Martin A, Schneiderman J, Helenowski IB, Morgan E, Dilley K, Danner-Koptik K, et al. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer. 2014;61:1350–6. https://doi.org/10.1002/pbc.25033.

Article  CAS  PubMed  Google Scholar 

Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, et al. Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017;72:177–85. https://doi.org/10.1016/j.ejca.2016.11.022.

Article  PubMed  Google Scholar 

Elzembely MM, Dahlberg AE, Pinto N, Leger KJ, Chow EJ, Park JR, et al. Late effects in high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell rescue. Pediatr Blood Cancer. 2019;66: e27421. https://doi.org/10.1002/pbc.27421.

Article  CAS  PubMed  Google Scholar 

Friedman DN, Henderson TO. Late effects and survivorship issues in patients with neuroblastoma. Children (Basel). 2018;5(8):107. https://doi.org/10.3390/children5080107.

Article  PubMed  Google Scholar 

Moke DJ, Luo C, Millstein J, Knight KR, Rassekh SR, Brooks B, et al. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. Lancet Child Adolesc Health. 2021;5:274–83. https://doi.org/10.1016/s2352-4642(21)00020-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson RA, et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019;25:673–93. https://doi.org/10.1093/humupd/dmz027.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laverdière C, Cheung NK, Kushner BH, Kramer K, Modak S, LaQuaglia MP, et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer. 2005;45:324–32. https://doi.org/10.1002/pbc.20331.

Article  PubMed  Google Scholar 

Schechter T, Perez-Albuerne E, Lin TF, Irwin MS, Essa M, Desai AV, et al. Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma. Bone Marrow Transplant. 2020;55:531–7. https://doi.org/10.1038/s41409-018-0298-y.

Article  CAS  PubMed  Google Scholar 

Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107:1045–53. https://doi.org/10.3324/haematol.2021.279189.

Article  PubMed  Google Scholar 

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, et al. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. 2016;7:4155–66. https://doi.org/10.18632/oncotarget.6393.

Article  PubMed  Google Scholar 

Kushner BH, Modak S, Kramer K, Basu EM, Iglesias-Cardenas F, Roberts SS, et al. Immunotherapy with anti-G(D2) monoclonal antibody in infants with high-risk neuroblastoma. Int J Cancer. 2023;152:259–66. https://doi.org/10.1002/ijc.34233.

Article  CAS  PubMed  Google Scholar 

Castel V, Canete A, Navarro S, Garcia-Miguel P, Melero C, Acha T, et al. Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol. 2001;37:537–42. https://doi.org/10.1002/mpo.1248.

Article  CAS  PubMed  Google Scholar 

De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol. 2003;21:1592–601. https://doi.org/10.1200/JCO.2003.05.191.

Article  CAS  PubMed  Google Scholar 

Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. J Clin Oncol. 2020;38:2160–9. https://doi.org/10.1200/jco.20.00203.

Article  CAS  PubMed  PubMed Central  Google Scholar